Since younger patients with pituitary tumors, particularly prolactinomas, have a higher prevalence of MEN1 mutations (7, 22), it might be expected that patients with clinical MEN-1 would also present with pituitary tumors at a younger age. This evidence concerns the gene MEN1 and multiple endocrine neoplasia type 1.